Trial Profile

A Phase I Clinical study of MTX652 in kidney disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MTX 652 (Primary)
Indications Acute kidney injury
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors MISSION Therapeutics

Most Recent Events

14 Dec 2023 Results presented in the MISSION Therapeutics Media Release.
02 Nov 2023 Results published in the MISSION Therapeutics Media Release
02 Nov 2023 According to a MISSION Therapeutics media release, the company will present an oral abstract at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com